Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for obsessive symptoms in bipolar disorder
IRCT20211118053093N4Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) and obsessive compulsive disorder (OCD) comparing Riluzole add-on with Placebo add-on (2 arms). Primary endpoints: Y-BOCS score at week 16 and Change in obsessive symptoms based on Y-BOCS at week 16. Started Aug 2022; status: completed.
02
Drugs
riluzole
03
Conditions
bipolar disorder (BD)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20211118053093N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211118053093N4.